Future work is expected to show if analysis of Mad2-targeting miRNAs’ expression and/or epigenetic status of the 14q32 locus has diagnostic value in cancer subtyping or in prediction of tumor cells’ sensitivity to clinically utilized microtubule drugs. This evidence concerns the gene MAD2L1 and cancer.